Maia Patent-Cliff Exposure & CMS Drug Spending Portfolio

Maia (US): 2 reconciled FDA prescription therapies, $363K 2024 CMS Part D & Medicaid spend, and $1,241 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$363K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$363K
California HCAI SB 17 FilingsSpecialty launch notice ($1,241 intro WAC)